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Background: Less than 20% of Pakistani women with early-onset or familial breast/ovarian cancer harbor germ line
mutations in the high-penetrance genes BRCA1, BRCA2 and TP53. Thus, mutations in other genes confer genetic
susceptibility to breast cancer, of which CHEK2 is a plausible candidate. CHEK2 encodes a checkpoint kinase,
involved in response to DNA damage.
Methods: In the present study we assessed the prevalence of CHEK2 germ line mutations in 145 BRCA1/2-negative
early-onset and familial breast/ovarian cancer patients from Pakistan (Group 1). Mutation analysis of the complete
CHEK2 coding region was performed using denaturing high-performance liquid chromatography analysis, followed
by DNA sequencing of variant fragments.
Results: Two potentially deleterious missense mutations, c.275C>G (p.P92R) and c.1216C>T, (p.R406C), were
identified (1.4%). The c.275C>G mutation is novel and has not been described in other populations. It was detected
in a 30-year-old breast cancer patient with a family history of breast and multiple other cancers. The c.1216C>T
mutation was found in a 34-year-old ovarian cancer patient from a family with two breast cancer cases. Both
mutations were not detected in 229 recently recruited BRCA1/2-negative high risk patients (Group 2).
Conclusion: Our findings suggest that CHEK2 mutations may not contribute significantly to breast/ovarian cancer
risk in Pakistani women.
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DNA damage results in activation of cell-cycle check-
points that inhibit cell proliferation and initiate DNA re-
pair. Impaired function of such checkpoints can lead to
genomic instability and susceptibility to cancer. CHEK2
(cell cycle checkpoint kinase 2, OMIM #604373) is a G2
checkpoint serine/threonine kinase that acts as a tumor
suppressor in the nucleus in response to DNA double-
strand breakage [1]. The CHEK2 protein is phosphory-
lated by ataxia-telangiectasia-mutated (ATM) [2] and
subsequently phosphorylates critical cell-cycle proteins
including TP53, CDC25C, CDC25A and BRCA1, pro-
moting cell cycle arrest, apoptosis and DNA repair [3-6].* Correspondence: u.hamann@dkfz-heidelberg.de
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reproduction in any medium, provided the orRecent studies have indicated that CHEK2 functions as
a moderately effective cancer susceptibility gene; muta-
tions in CHEK2 predispose individuals to breast cancer
[7-10] as well cancer of other sites [11-13]. Thus far, five
deleterious recurrent mutations in CHEK2 have been
identified that confer about twofold elevated risk of
breast cancer in unselected female population. These
include the truncating mutation CHEK2 c.1100delC
[14,15], the missense mutations p.I157T and p.S428F
[7,16], the splice site mutation c.IVS2 +1G>A [7,17] and
the large genomic 5,395 bp deletion (del5395) [18]. For
carriers of the c.1100delC mutation, even higher risk of
up to three to five fold was observed among early-onset
and familial breast cancer patients [14,15].
The frequencies of these mutations have been shown to
vary widely with geographic distribution and ethnicity
[19-32]. The prevalence of c.1100delC ranged from beingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from North-Europe [33], while it was not detected in
breast cancer patients from Asia, including China, Korea,
Malaysia, Singapore, Japan, the Philippines, India and
Pakistan [20-23,28-32]. The variants c.IVS2 +1G>A and
del5395 were identified in Poland [7,18], Belarus [17,34],
Russia [35] and Czech Republic [36] with a frequency of
0.7%-1.1% and 0.9%-1.3%, respectively; p.S428F was identi-
fied in the Ashkenazi Jewish population with a frequency
of 2.9% [16] and p.I157T in Finland with a prevalence of
7.4% [26].
The role of CHEK2 mutations in breast cancer predis-
position has been investigated previously in several studies
conducted in Asia. Whereas most studies restricted the
analysis to the CHEK2 c.1100delC mutation [20-23,28-32],
the study performed by Liu and colleagues included the
entire gene [37]. In this study conducted in China a
novel pathogenic missense mutation, p.H371Y, was
identified in familial and unselected breast cancer cases
and controls with a frequency of 4.2%, 1.8% and 0.7%,
respectively. These results suggest that CHEK2 germ
line mutations may contribute to breast cancer suscep-
tibility in the Chinese population and point to the need
of more whole mutational screens in other Asian
populations.
Given the paucity of data on genetic variability of
CHEK2 in Asian populations coupled with the fact that
less than 20% of Pakistani women with early-onset or
familial breast/ovarian cancer can be attributed to germ
line mutations in BRCA1, BRCA2 and TP53 [38,39], we
assessed the prevalence of CHEK2 mutations in 145 high-
risk BRCA1/2-negative breast/ovarian cancer patients
from Pakistan (Group 1). Comprehensive mutation ana-
lysis of the entire coding region and the exon-intron junc-
tions of the CHEK2 gene were performed. An additional
group of 229 high-risk BRCA1/2-negative breast/ovarian




The study included index patients from 145 breast and/or
ovarian cancer families who have been assessed and con-
firmed to be negative for BRCA1/2 germ line mutations
and described previously (Group 1) [38]. After identifica-
tion of mutations from the entire coding region of the
CHEK2 gene in this cohort, an additional cohort of 229
BRCA1/2-negative high-risk patients was screened for
the two identified mutations (Group 2). The index cases
were identified using the following criteria: i) families
with one female breast cancer diagnosed ≤30 years of
age, ii) families with two first- or second-degree (through
a male) female relatives diagnosed with breast cancer; at
least one diagnosed ≤50 years of age, iii) families with atleast three cases of breast cancer; at least one diagnosed
≤50 years of age, iv) families with one male breast cancer
case diagnosed at any age, v) families with at least one
female breast cancer and one ovarian cancer at any age,
vi) families with one ovarian cancer diagnosed ≤45 years
of age and vii) families with at least two ovarian cancers;
at least one diagnosed ≤45 years of age. Breast and ovarian
cancer in the same patient were counted as two indepen-
dent cases. The number of index cases by phenotype for
Group 1 and Group 2 are shown in Table 1.
Control population comprised 150 healthy females of
Pakistani origin. These were either attendants of hospital
registered patients or visiting the cancer centre for med-
ical reasons other than cancer. All study participants
were furnished with and signed an informed written
consent. The study was approved by the Institutional
Review Board of the SKMCH & RC.
Mutation screening
Genomic DNA was extracted as previously described [38].
The entire coding region and exon-intron junctions of the
CHEK2 gene (Genbank accession number NM_007194.2)
were screened in the 145 index patients using denaturing
high-performance liquid chromatography (DHPLC) ana-
lysis. DHPLC analysis was carried out with the WAVE
system (Transgenomics, Omaha, NE). Since multiple
homologous copies are present for exons 10–14 of this
gene, a nested PCR approach was employed as previously
described [40]. PCR-primer pairs and DHPLC running
conditions for exon 1 and exons 4–14 were according to
Dufault and colleagues [41] and for exons 2 and 3
according to Kleibl and colleagues [42]. When available, a
mutation positive control for each exon was included in
the DHPLC analyses.
The presence of the CHEK2 mutations identified in
Group 1 was subsequently assessed in the 229 BRCA1/
2-negative high-risk cases of Group 2 and in 150 healthy
female controls.
DNA sequence analysis
Each sample showing variants detected by DHPLC
analysis was sequenced using an automated DNA CEQ
8000 sequencer (Beckman, Hilden, Germany) according
to the manufacturers’ instructions. Bi-directional genomic
DNA sequencing was performed to verify the presence of
a mutation.
In silico analyses
CHEK2 missense variants (p.P92R; p.R406C) were ana-
lyzed for their potential effect on protein function using
the default settings of web tools Align-GVGD (http://
agvgd.iarc.fr/agvgd_input.php), PolyPhen2 (http://genet-
ics.bwh.harvard.edu/pph2), SIFT (http://sift.jcvi.org) and
SNAP (http://www.rostlab.org/services/snap).
Table 1 Description of index cases screened for CHEK2 mutations
Cancer type
of index case
Phenotype of familiesa Number of
families







Unilateral BC Bilateral BC
Group I
Female cases
BC Early onset BC (1 case ≤30 years) 66 66 - 27.2 (22–30) 1 (1.5)
BC HBC (2 cases, ≥1 diagnosed ≤50 years) 30 17 13 34.2 (22–48) 0 (0)
BC HBC (≥3 cases, ≥1 diagnosed ≤50 years) 9 5 4 38.1 (24–70) 0 (0)
BC HBOC (≥2 cases) 2 2 - 41.5 (35–48) 0 (0)
BC & OCb HBOC (≥2 cases) 4 3 1 31.2 (29–34) 0 (0)
OC HBOC (≥2 cases) 2 - - 31 (28–34) 1 (50)
OC Early onset OC (1 case ≤45 years) 19 - - 33.2 (22–45) 0 (0)
OC HOC (2 cases, ≥1 diagnosed ≤45 years) 2 - - 34 (31–37) 0 (0)
Male cases
BC Male BC 11 11 - 48 (30–73) 0 (0)
All casesc 145 104 18 2 (1.4)
Group II
Female cases
BC Early onset BC (1 case ≤30 years) 103 103 - 27.1 (19–30) 0 (0)
BC HBC (2 cases, ≥1 diagnosed ≤50 years) 55 49 6 40.8 (19–61) 0 (0)
BC HBC (≥3 cases, ≥1 diagnosed ≤50 years) 53 47 6 44.4 (26–73) 0 (0)
BC HBOC (≥2 cases) 8 7 1 49 (26–67) 0 (0)
BC & OCb HBOC (≥2 cases) 3 2 1 45.6 (30–59) 0 (0)
OC HBOC (≥2 cases) 5 - - 43.2 (33–60) 0 (0)
OC Early onset OC (1 case ≤45 years) 2 - - 30.5 (25–36) 0 (0)
All casesd 229 208 14 0 (0)
BC, breast cancer; HBC, hereditary breast cancer; HBOC, hereditary breast and ovarian cancer; HOC, hereditary ovarian cancer; OC, ovarian cancer.
asee “Study subjects in Method section”.
bBreast and ovarian cancer in the same patient were counted as two independent cases.
cIncluding 111 female BCs, 11 male BCs and 27 OCs.
dIncluding 222 female BCs and 10 OCs.
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We studied 145 unrelated affected index patients from
Pakistani breast and/or ovarian cancer families all of
whom have previously been tested and found to be
negative for BRCA1/2 germ line mutations (Group 1).
The median age of onset of disease was 29 years (range
22–70) for female breast cancer (n = 111), 45 years
(range 30–73) for male breast cancer (n = 11) and 33 years
(range 22–45) for ovarian cancer (n = 27). Eighteen of 111
(16.2%) women were diagnosed with bilateral breast can-
cer. Five cases reported a relative affected with colorectal
or prostate cancer.
The joint approach of DHPLC and DNA sequencing
analysis revealed ten CHEK2 sequence variants: one si-
lent mutation, three missense mutations and six intronic
variants (Table 2).
Two missense potentially functional mutations, c.275C>G
(p.P92R) and c.1216C>T (p.R406C) were identified in 2out of the 145 (1.4%) breast/ovarian cancer families
(Table 1). c.275C>G (p.P92R) is a novel mutation that
has not previously been reported in other populations
(Additional file 1: Figure S1). It was detected in a 30-
year-old early-onset breast cancer patient (IV:3) of
Punjabi ethnicity, who presented with a grade 3, lymph
node positive, invasive ductal carcinoma, positive for
expression of estrogen receptor (ER), progesterone
receptor (PR) and epidermal growth factor receptor 2
(HER2) (data not shown). The mutation was also found
in another distant paternal female relative, who was di-
agnosed with breast cancer at 53 years of age (III:9)
(Additional file 2: Figure S2A). On the paternal side of
the index patient, two more female breast cancers, one
bilateral disease diagnosed at 30 and 60 years of age and
the other at unknown age, one intestinal cancer, one
lung cancer, one cancer of unknown type and one
Hodgkin lymphoma were reported. To predict the
Table 2 CHEK2 germ line mutations and nucleotide changes in non-BRCA1/2-associated early-onset and familial breast/
ovarian cancer patients from Pakistan
Location Coding (c.) DNA sequencea Effect SNP Linkb Classificationc Prevalence
Group 1 Group 2
Cases (n = 145)
n (%)
Cases (n = 229)
n (%)
Controls (n = 150)
n (%)
Exon 1 c.252A>G (E84E) Silent rs1805129 P 13 (8.9) 18 (7.9) 12 (8.0)
Exon 1 c.275C>G (P92R) Missense - M 1 (0.7) 0 (0) 0 (0)
Exon 10 c.1216C>T (R406C) Missense - M 1 (0.7) 0 (0) 0 (0)
Exon 13 c.1501G>A (E501K) Missense rs17883172 P 3 (2.1) 1 (0.4) 0 (0)
Intron 1 c.319 +43_319 +44insA Intronic rs17879991 P 64 (44.1) - 47 (31.3)
Intron 3 c.592 +50A>T Intronic rs17881298 P 1 (0.7) - 0 (0)
Intron 4 c.683 +119_683 +122delATTT Intronic - P 2 (1.4) - 1 (0.7)
Intron 4 c.684 -78_-100dup23 Intronic - P 16 (11.0) - 20 (13.3)
Intron 7 c.908 +48dupA Intronic - VUS 1 (0.7) - 0 (0)
Intron 13 c.1542 +92dupA Intronic - VUS 1 (0.7) - 0 (0)
Novel germ line mutations and nucleotide changes are marked in bold.
P, polymorphism; M, mutation; VUS, variant of unknown significance.
aNomenclature follows Human Genome Variation Society (HGVS) (http://www.hgvs.org). Numbering starts at the first A of the first coding ATG (located in exon 2)
of NCBI GenBank Accession NM_007194.
bLink to NCBI SNP database (http://ncbi.nlm.nih.gov/projects/SNP/).
cClassification of missense mutations is based on in silico analyses.
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were performed using the computational tools Align-
GVGD, PolyPhen2, SIFT and SNAP. The mutation was
predicted to be likely pathogenic by PolyPhen2 and
SNAP.
The other missense mutation c.1216C>T (p.R406C)
was found in a patient from Punjab, who was diagnosed
with ovarian cancer at age 34 (IV:2). The mother of
the index patient and a maternal aunt of the mother
were diagnosed with breast cancer at 38 years of age
and at unknown age, respectively (Additional file 2:
Figure S2B). The mutation carrier presented with a
high grade papillary serous carcinoma. This germ line
mutation has previously been reported in two female
breast cancer patients [43,44] and was predicted to be
likely pathogenic in silico [43].
Both missense mutations are rare as they were not
detected in Group 2 that included 229 patients with
BRCA1/2-negative breast/ovarian cancer or the 150
healthy female controls indicating that they may be
disease-causative.
Of the other described CHEK2 variants, the silent muta-
tion, one missense mutation and three intronic variants
have been previously classified as polymorphisms (Table 2).
Three of these (c.252A>G, c.319 +43_319 +44insA and
c.592 +50A>T) have also been identified in the NHLBI
Exome Sequencing Project (http://evs.gs.washington.edu/
EVS/). Three novel variants are located in introns and are
deemed unlikely to have a functional effect.Discussion
The relevance of CHEK2 mutations as a screening target
for an elevated risk of breast cancer is of interest. Given
the variability among different populations the frequency
within a given population needs to be ascertained to qual-
ify relevance. Our contribution to this area of investigation
was to establish relevance in the BRCA1/2-negative
high-risk breast/ovarian cancer Pakistani population by
assessing the prevalence of CHEK2 mutations. While
only one Asian study conducted in China has investi-
gated the frequency of CHEK2 germ line mutations
using the whole gene screen [37], our study will provide
additional information on genetic variability of the
CHEK2 gene in an Asian population from Pakistan.
The risk conferred by CHEK2 germ line mutations to
breast and ovarian cancer in Asian populations is not
well defined since most studies have determined the fre-
quency of the c.1100delC mutation but did not evaluate
other mutations. This holds true for studies conducted
in Korea [23], Malaysia [31], Singapore [28], Japan [21],
China [22,32], India [29,30], Pakistan and the Philippines
[20]. In the present study we investigated the entire
CHEK2 coding sequence including the exon-intron junc-
tions using DHPLC analysis followed by direct DNA se-
quencing of variant fragments. Two potentially deleterious
missense mutations, novel p.P92R and p.R406C, were
identified in two unrelated patients. Both mutations are
rare as they were not detected in a second group of 229
BRCA1/2-negative early-onset and familial breast/ovarian
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they may be associated with the disease. Our findings sug-
gest that CHEK2 missense mutations may not contribute
significantly to breast/ovarian cancer susceptibility in
Pakistan. In a study conducted in China that looked at
CHEK2 mutations based on whole gene analysis, a novel
recurrent missense mutation, p.H371Y, was identified in
5/118 (4.2%) familial and 16/909 (1.8%) unselected breast
cancer patients and in 9/1,228 (0.7%) controls [37]. The
results of this study and the present one suggest that
CHEK2 germ line mutations may contribute to breast can-
cer susceptibility in populations from East Asia, but may
play a minor role in a South Asian population from
Pakistan. Our data on the absence of the c.1100delC mu-
tation in Pakistan are in line with those of previous studies
[20-23,28-32] supporting the notion that c.1100delC does
not contribute to breast cancer susceptibility in Asian
populations.
In contrast to the single study of a whole CHEK2 gene
screen in an Asian population, many studies have been
performed in Caucasian populations reporting different
mutations and mutation frequencies in the range from
0% to 12%. In the French-Canadian population no muta-
tions were detected in 25 (0%) BRCA1/2-negative famil-
ial breast cancer patients [19]. In France mutations were
found in 15/507 (2.9%) BRCA1/2-negative familial breast
cancer cases [25]. In the United States mutations were
observed in 5/169 (3%) early-onset breast cancer
patients (≤40 years) [21] and in another study mutations
were identified in 51/1,303 (3.9%) early-onset patients
(≤45 years) from the United States, Canada and Australia
[43]. The highest mutation frequencies were reported in
30/516 (5.8%) BRCA1/2-negative familial breast cancer
patients from Germany [41], 10/172 (5.8%) Ashkenazi
Jewish familial BRCA1/2-founder mutation-negative
breast and/or ovarian cancer patients or unaffected
women [45], 8/89 (8.9%) familial breast cancer patients
from the UK, North America and the Netherlands [46]
and in 10/82 (12.2%) familial BRCA1/2-founder mutation-
negative breast and/or ovarian cancer patients from
Finland [27].
Mutation screening was performed using the com-
bined approach of DHPLC analysis followed by DNA se-
quencing of variant fragments. DHPLC has been
commonly used for mutation screening of various genes
as it is rapid, cost-effective and highly sensitive detecting
93 to 100% of mutations that were observed by DNA se-
quencing [47]. However, since the DHPLC mutation de-
tection rate is not 100% for each gene, it cannot be ruled
out that some mutations were missed. CHEK2 mutation
analysis is hampered by the presence of multiple homol-
ogous copies for exons 10–14 and requires an adapted
primer design and amplification conditions. In the
present study we employed a nested PCR strategy thatspecifically amplified the functional copy of the CHEK2
gene [40].
The CHEK2 mutation frequency of 2/145 (1.4%) ob-
served in this study may be an underestimate as the sen-
sitivity of DHPLC can be below 100% and screening for
regulatory mutations residing outside the coding region
and for large genomic rearrangements was not per-
formed. Previously a large genomic deletion of 5,395 bp,
which results in loss of exons 9 and 10, has been identi-
fied in two families of Czechoslovakian ancestry, in a
series of Czech and Slovak breast cancer patients (8/631,
1.3%) enriched for familial cases and was absent in 367
controls [36]. In Poland the same deletion was detected in
19/1,978 (1.0%) unselected breast cancer cases, 28/3,228
(0.9%) early-onset cases and in 24/5,496 (0.4%) controls
[18]. Thus further analyses for genomic rearrangements
in Asian populations may reveal additional CHEK2
mutations as well.
In the present study a novel missense mutation, p.P92R,
was identified in a young Pakistani breast cancer patient
of Punjabi origin from a family with multiple breast can-
cers, intestinal cancer, lung cancer, cancer of unknown
type and Hodgkin lymphoma. The mutation was also
found in another paternal female relative diagnosed with
breast cancer at 53 years of age. Since CHEK2 is known to
be a multi-organ cancer susceptibility gene [7], the muta-
tion may have co-segregated with the disease in this fam-
ily. However, this could not be tested since DNA samples
of relevant family members were not available for analysis.
The other mutation, p.R406C, was found in a young
Punjabi patient diagnosed with ovarian papillary serous
carcinoma, who reported a family history of breast cancer.
The same mutation has previously been observed in a
Spanish familial breast cancer patient and in an early-
onset breast cancer patient (≤45 years) of unknown ances-
try, but was absent in 400 healthy controls from Spain and
1,109 controls from Canada, the USA and Australia
[43,44]. Due to the lack of DNA samples of relevant family
members, co-segregation of this mutation with cancer
could not be studied.
The breast tumor of the patient harboring the p.P92R
missense mutation was positive for ER, which is consist-
ent with previous findings that breast tumors linked with
CHEK2 frame shift and missense mutations (c.1100delC,
c.IVS2 +1G>A, del5395, p.I157T) are predominantly ER-
positive [48-50]. Additionally, an association of the
CHEK2 p.I157T missense mutation has been reported
with lobular carcinoma [50,51]. This link was not observed
with the novel p.P92R missense mutation in the present
study given the only p.P92R-associated tumor was invasive
ductal carcinoma. Given the solitary finding, no interpre-
tation could be rendered.
Our study included cases and controls from only one
ethnic group providing uniformity of subjects, adding to
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BRCA1/2 testing by virtue of having an early-onset of
disease or a family history suggestive of hereditary
breast/ovarian cancer [38]. Genetic variability in CHEK2
was analyzed in a whole gene screen and was not re-
stricted to the few regions with known CHEK2 muta-
tions. Limitations of the present study are that the
functional effects p.P92R and p.R406C and the frequency
of large genomic rearrangements were not investigated.Conclusions
In this first study of the prevalence of CHEK2 germ line
mutations in 145 BRCA1/2-negative early-onset and fa-
milial breast and/or ovarian cancer from Pakistan two
potentially deleterious mutations were identified. Both
mutations are rare as they were not found in 229 other
high-risk patients. Our findings suggests that CHEK2
germ line mutations play a negligible role in early-onset
and familial breast/ovarian cancer in Pakistan and imply
that CHEK2 mutation screening of high-risk patients is
not warranted in this population.Additional files
Additional file 1: Figure S1. DNA mutation analysis of CHEK2 c.275C>G
(P92R). DNA sequencing chromatograms of the forward strand showing
the region containing the c.275C>G sequence of healthy control sample
(A) and corresponding interval from DNA of a c.275C>G mutation carrier
(B). The arrow indicates the position of the mutation in the
chromatogram. S, C>G.
Additional file 2: Figure S2. Pedigrees of CHEK2 c.275C>G (A) and
c.1216C>T (B) mutation carrier Families 112 and 171. Circles are females,
squares are males, and a diagonal slash indicates a deceased individual.
Symbols with filled left upper quadrant: unilateral breast cancer. Symbols
with filled upper half circle: bilateral breast cancer. Symbols with filled left
lower quadrant: ovarian cancer. Symbols with filled right lower quadrant:
cancer other than breast cancer, cancer type is indicated. Identification
numbers of individuals are below the symbols. The index patient is
indicated by an arrow. A, age; BC, breast cancer; HD, Hodgkin’s disease;
OC, ovarian cancer; CA, cancer; D, death. The numbers following these
abbreviations indicate age at recruitment, age at cancer diagnosis and
age at death. M+, mutation positive. M-, mutation negative.Abbreviations
CHEK2: Cell cycle checkpoint kinase 2 gene; DHPLC: Denaturing high-
performance liquid chromatography.Competing interests
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